Metsera (NASDAQ:MTSR) Shares Down 4% - Should You Sell?

Shares of Metsera, Inc. (NASDAQ:MTSR - Get Free Report) were down 4% on Thursday . The company traded as low as $28.20 and last traded at $28.68. Approximately 22,857 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 566,749 shares. The stock had previously closed at $29.86.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MTSR. Cantor Fitzgerald assumed coverage on Metsera in a research note on Tuesday, February 25th. They set an "overweight" rating on the stock. Guggenheim assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $56.00 price target on the stock. Evercore ISI assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating for the company. Finally, Bank of America began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price on the stock.

Metsera Stock Up 7.2 %

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.